ruski

The influence of antihypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arteries pressure in patients with arterial hypertension of 1-2 grades in international VICTORY clinical trial

Objective-to explore influence of valsartan monotherapy use and its use in combination with hydrochlorothiazide (HCTZ) on npulse-wave velocity (PWV) and central arterial pressure (CAP) in patients with arterial hypertension (AH) of 1-2 grades in international VICTORY clinical trial. The international multicenter prospective randomized clinical study VICTORY that lasted for 16 weeks included patients with 1-2 grades AH. In patients who previously received antihypertensive therapy a 7 days washout period was carried out. All patients started their therapy with 80 mg valsartan (Vlasacor, KRKA, Slovenia) ; in Russia the starter dose of Valsacor KRKA was 160 mg in previously treated patients that did not influence the study results. PWV and CAP (SphygmoCor, AtCorMedical) were assessed at baseline and after 15 weeks treatment. Of 365 patients included in the study 74 were included in PWV and CAP study subgroup. Valsartan and its combination with HCTZ were effective in CAP reduction. In VICTORY study valsartan use for 16 weeeks as monotherapy and in combination with HTCZ resulted in aortic stiffness reduction in patients with 1-2 grades AH, that may lead to patient's prognosis improvement and risk of cardiovascular events reduction

Valsartan ; Hydrochlorothiazide ; Arterial hypertension ; Pulse-wave velocity ; Central arterial pressure ; Clinical trial VICTORY

nije evidentirano